ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,275.38
0.54%
Dow Jones
38,686.32
1.51%
Gold vs US Dollar
2,327.355
0.00%
Brent Oil
81.295
0.00%
Bitcoin
67,712.38
0.34%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lipella Pharmaceuticals Inc (LIPO)

  7. Lipella Pharmaceuticals Inc (LIPO) News

Lipella Pharmaceuticals (LIPO)

Lipella Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LIPO
DateTimeSourceHeadlineSymbolCompany
31/05/202413:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen PlanusNASDAQ:LIPOLipella Pharmaceuticals Inc
29/05/202413:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:LIPOLipella Pharmaceuticals Inc
21/05/202413:00GlobeNewswire Inc.Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2bNASDAQ:LIPOLipella Pharmaceuticals Inc
15/05/202421:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIPOLipella Pharmaceuticals Inc
09/05/202421:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
06/05/202421:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
17/04/202413:00GlobeNewswire Inc.Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology ExpertiseNASDAQ:LIPOLipella Pharmaceuticals Inc
05/04/202413:00GlobeNewswire Inc.Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024NASDAQ:LIPOLipella Pharmaceuticals Inc
03/04/202413:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic CystitisNASDAQ:LIPOLipella Pharmaceuticals Inc
07/03/202420:23GlobeNewswire Inc.PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
06/03/202422:05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
06/03/202422:03Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
05/03/202413:00GlobeNewswire Inc.Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical PipelineNASDAQ:LIPOLipella Pharmaceuticals Inc
27/02/202422:04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
27/02/202421:51Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LIPOLipella Pharmaceuticals Inc
20/02/202413:00GlobeNewswire Inc.Lipella Pharmaceuticals to Present at PropThink Digital Investor ConferenceNASDAQ:LIPOLipella Pharmaceuticals Inc
09/02/202405:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
07/02/202422:29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
01/02/202421:09Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIPOLipella Pharmaceuticals Inc
25/01/202421:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LIPOLipella Pharmaceuticals Inc
03/01/202421:59Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LIPOLipella Pharmaceuticals Inc
20/12/202313:00GlobeNewswire Inc.Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones AccomplishedNASDAQ:LIPOLipella Pharmaceuticals Inc
28/11/202322:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
22/11/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIPOLipella Pharmaceuticals Inc
14/11/202311:22Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
14/11/202311:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIPOLipella Pharmaceuticals Inc
10/11/202313:00PR Newswire (US)FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseNASDAQ:LIPOLipella Pharmaceuticals Inc
09/11/202321:07Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LIPOLipella Pharmaceuticals Inc
09/11/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIPOLipella Pharmaceuticals Inc
07/11/202322:22Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:LIPOLipella Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LIPO

Your Recent History

LSE
49DM
Mound Fin.4 3cs
LSE
GBEG
Ivz Gbl Cb Gbp
LSE
AQ87
Hsbc Bk.28
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved